More than two years into the GLP-1 injectable shortage, drugmakers Eli Lilly and Novo Nordisk have asked FDA to take emergency action to prohibit compounding of tirzepatide and semaglutide, the active pharmaceutical ingredients in both the brand-name and compounded GLP-1 injectables. 

It’s an audacious ask, considering millions of doses have safely been prepared and dispensed by compounding pharmacies across the U.S. over the last two years.

The drugmaker claims misrepresent the facts – including the fact that patients who are taking compounded GLP-1s are benefiting from them.

FDA NEEDS TO HEAR FROM YOU NOW

Urge FDA to reject the requests by Eli Lilly and Novo Nordisk to prohibit the compounding of tirzepatide and semaglutide. 

If a compounded version of one of those drugs has been a life-line for you during this shortage, share your story. 

We’ve made it easy for you. The letter is written. All you have to do is add your name. It takes about two minutes.

Thanks for your help in preserving patient access to compounded GLP-1 drugs.